Rheumnow Podcast
Dr Jack Cush reviews the news, journal reports and regulatory decisions from the past week on RheumNow.com
Latest episodes
Jun 13, 2024 • 41min
EULAR 2024 Daily Recap - Days 1 & 2
Moderated by Dr. Jack Cush and featuring Dr. Yuz Yusof and Dr. Mrinalini Dey
Jun 13, 2024 • 4min
Mechanistic Promise in RA Doesn’t Always Mean Actual Gain
Dr. David Liew reports on abstracts OP0007 and OP0069 at Eular 2024 in Vienna, Austria.
Jun 13, 2024 • 4min
The Role of Psychosocial Determinants in the Management of Rheumatoid Arthritis
Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309.
Jun 13, 2024 • 5min
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Jun 13, 2024 • 4min
Voclosporin and Steroids in Lupus Nephritis
Dr. Jack Cush reports on abstract OP0059 presented at Eular 2024 in Vienna, Austria.
Jun 13, 2024 • 2min
3 Big Lupus Themes from EULAR 2024
Dr. Janet Pope discusses three hot topics in lupus at Eular 2024 in Vienna, Austria.
Jun 13, 2024 • 6min
Does B Cell Depletion Matter?
Drs. Yuz Yusof and Ed Vital discuss abstract OP0077 at Eular 2024 in Vienna, Austria.
Jun 13, 2024 • 3min
Do MRI changes at the Spine and SI Joints in Treatment of AxSpA Matter?
Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria.
OP0046 Effect on SI joint structural lesions with ixekizumab
POS0058 Effect on SI joint structural lesions with bimekizumab
Jun 13, 2024 • 5min
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
Jun 13, 2024 • 5min
Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis?
Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at Eular 2024 in Vienna, Austria:
OP0195 Sonelokimab IL 17 A/F nanobody inhibitor
LB0005 Izokibep IL17A nanobody inhibitor
POS0803 Vunakizumab, another IL17A inhibitor
OP0138 TAK-279 phase 2B selective TYK2 inhibitor Zasocitinib
